Abstracts tagged "DMARDs"

Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Edward Bernton¹ and Valerie Lowe², ¹Protalex Inc., Summit, NJ, ²Washington Biotechnology, Inc., Baltimore, MD
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…
Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting
Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Diane Sauvageau³, Jean Pierre Pelletier¹, Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Birgul Ay¹, Dilek Keskin², Goksal Keskin³ and Ayhan Dinc⁴, ¹Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, ²Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ⁴Rheumatology, Patio Clinic, Ankara, Turkey
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
Abstract Number: 1760 • 2013 ACR/ARHP Annual Meeting
Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt
Jennifer M. Polinski¹, M. Alan Brookhart², John Z. Ayanian³, Jeffrey N. Katz⁴, Seo Young Kim⁵, Chris Tonner⁶, Edward H. Yelin⁷ and Daniel H. Solomon^8,9, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²University of North Carolina, Chapel Hill, NC, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are recommended for all patients with rheumatoid arthritis (RA). Some studies estimate that almost half of patients with RA do…
Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
G. R. Burmester¹, C Charles-Schoeman², J. D. Isaacs³, T. Hendrikx⁴, K. Kwok⁵, S. H. Zwillich⁶ and R. Riese⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²University of California, Los Angeles, CA, ³Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Pfizer BV, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
Abstract Number: 1713 • 2013 ACR/ARHP Annual Meeting
Disparity In Biologic Therapy In Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due To Lack Of Access To Drug?
Gail S. Kerr¹, Ted R. Mikuls², Christopher J. Swearingen³, Chunqiao Luo⁴ and Yusuf Yazici⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Ethnic disparities in the administration of DMARDs exist, but the impact of differing health care systems on access in ethnic minorities treated by rheumatologists,…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
P.H.P. de Jong¹, J.M.W. Hazes², K.H. Han³, A.M. Huisman⁴, D. van Zeben⁵, P.A. van der Lubbe⁶, A.H. Gerards⁶, B. van Schaeybroeck⁷, P.B. de Sonnaville⁸, M.V. Krugten⁹, J.J. Luime² and A.E.A.M. Weel³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…
Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
J. M. Kremer¹, J. D. Greenberg², C. Turesson³, D. Gruben⁴, C. A. Mebus⁴, E. Bananis⁵ and T. Robinson⁶, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ³Lund University, Malmö, Sweden, ⁴Pfizer Inc, Groton, CT, ⁵Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
Abstract Number: 361 • 2013 ACR/ARHP Annual Meeting
Risk Of Venous Thromboembolism and Use Of Disease-Modifying Antirheumatic Drugs For Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon^2,3, Jun Liu⁴, Jessica M. Franklin⁵, Robert J. Glynn⁶ and Sebastian Schneeweiss⁷, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent research suggests that rheumatoid arthritis (RA), an autoimmune systemic inflammatory disease, increases the risk of venous thromboembolism (VTE) including pulmonary embolism and deep…
Abstract Number: 198 • 2013 ACR/ARHP Annual Meeting
Accuracy Of International Classification Of Diseases (Ninth Revision) Coding For Rheumatoid Arthritis In The Primary Care Setting
Sheena Ogando¹, Karolina M. Weiss¹ and Harry D. Fischer², ¹Department of Medicine, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY, ²Division of Rheumatology, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY
Background/Purpose: Current quality measures are diagnosis driven and focus on management. For rheumatoid arthritis (RA), the Physician Quality Reporting System requires that a disease modifying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].